Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
Pilot Feasibility Study of the Interplay Between the Host Gut Microbiome and Efficacy of Treatment for Advanced or Recurrent Gynecological Cancer Patients Receiving Immunotherapy
Sponsor: AdventHealth
Listed as NCT04957511, this observational or N/A phase trial focuses on Gut Microbiome and Gynecologic Cancer and remains actively recruiting participants. Sponsored by AdventHealth, it has been updated 7 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Feb 2025 — Present [monthly]
Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2023 — Jul 2024 [monthly]
Recruiting
-
Dec 2021 — Jul 2023 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AdventHealth
- Viome
For direct contact, visit the study record on ClinicalTrials.gov .